HOB Biotech Group (688656) Fundamentals 2026 — P/E 245.8x, Revenue Analysis | SniperIQ
HOB Biotech Group (688656) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of ¥5.2B, trading at ¥82.56 on the SHH. This SniperIQ fundamentals page covers HOB Biotech Group's valuation (P/E 245.8x, P/B 6.3x), profitability (net margin 5.4%), revenue (¥398M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is HOB Biotech Group's market cap?
HOB Biotech Group (688656) has a market capitalization of approximately ¥5.2B, trading at ¥82.56 on the SHH. Market cap moves with the live share price.
What is HOB Biotech Group's P/E ratio?
HOB Biotech Group's trailing twelve-month P/E ratio is 245.8x, with a price-to-book (P/B) of 6.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is HOB Biotech Group?
HOB Biotech Group runs a net profit margin of 5.4%, a gross margin of 58.2%, and an operating margin of 6.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does HOB Biotech Group generate?
HOB Biotech Group reported revenue of ¥398M for fiscal year 2025, with net income of ¥23M and earnings per share (EPS) of 0.37. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does HOB Biotech Group pay a dividend?
HOB Biotech Group offers a trailing dividend yield of about 0.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is HOB Biotech Group financially healthy?
HOB Biotech Group carries a debt-to-equity ratio of 0.04x and a current ratio of 2.75x, with a market beta of -0.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is HOB Biotech Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For HOB Biotech Group (688656) the key facts are: market cap ¥5.2B, P/E 245.8x, revenue ¥398M, 52-week range 76.62-217. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track HOB Biotech Group's full fundamentals live
Get HOB Biotech Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.